An FDA advisory committee voted 9-3 against the effectiveness of Capricor Therapeutics' (NASDAQ: CAPR) Deramiocel for treating cardiomyopathy in patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE